Published Research

Research Article | Open Access

Volume 2022 |Article ID 1558860 | https://doi.org/10.1155/2022/1558860

Palayakotai R. Raghavan, “Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro”, BioMed Research International, vol. 2022, Article ID 1558860, 14 pages, 2022. https://doi.org/10.1155/2022/1558860

Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro

---

Palayakotai R. Raghavan¹

¹Nanorx Inc., P.O. Box 131 Chappaqua, NY 10514, USA

Academic Editor: Cassiano Felippe Gonçalves-de-Albuquerque

Received30 Apr 2021

Revised20 Oct 2021

Accepted15 Dec 2021

Published15 Jan 2022

https://www.hindawi.com/journals/bmri/2022/1558860

4. Summary and Conclusions

Metadichol inhibits the entry of SARS-CoV-2 into host cells by inhibiting TMPRSS2, thus allowing ACE2 to play a critical role in the renin-angiotensin pathway. In addition, it enhances the antiviral response of the host by increasing the innate and adaptive immune responses through the vitamin D pathway and by endogenously increasing the vitamin C levels. In addition, telomerase activity also plays a key role in maintaining the levels of naive T and B cells required to fight infections. Metadichol modulates cytokine storms, as it is an inhibitor of TNF, ICAM1, and CCL2 that play a key role in generating cytokine storms. Metadichol also regulates COVID-19-associated comorbidities [86, 87], such as hypertension and diabetes [88–90]. Thus, Metadichol has the potential to improve the long-term prognosis of the affected patient population. Metadichol acts on multiple genes and has over 2000 unique gene interactions, thereby resulting in a network that brings about homeostasis and prevents SARS-CoV-2 infections.

Metadichol is a safe, noncytotoxic product. LD₅₀ is greater than 5000 mg per kilo in rat studies. It is made from renewable sources like sugar cane or rice. It has been commercially available for the last six years and has no reported side effects. Thus, Metadichol can potentially be used as an immune modulator to prevent future occurrences of SARS-CoV-2 and possibly other predicted infections, facilitating a rapid return to normal social and economic human activities worldwide.